About John Curnutte
John Curnutte is a director at Neuvivo, which develops therapies for ALS and other diseases of the nervous system. He also serves on the boards of Pliant Therapeutics and Cayuga Biotech. He advises Samsara BioCapital and Astra Zeneca.
From February 2011 to May 2019, Curnutte led research and development at Portola Pharmaceuticals as executive vice president, then remained a consultant. Earlier, he was chief executive officer of 3-V Biosciences and president of Schering-Plough Biopharma. He held senior posts at Genentech and a tenured faculty role at The Scripps Research Institute. He taught pediatrics and served on Stanford's medical staff from 1993 to 2013. He earned a Harvard bachelor's in biochemistry and molecular biology, plus a medical degree and biological chemistry doctorate from Harvard Medical School. He served on Diadexus's board from 2015 to 2016. He joined Orchard Therapeutics' board in 2019 and left before Kyowa Kirin acquired it.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name John Curnutte in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people John Curnutte works with at each company, as listed on that company's latest Form D.